Literature DB >> 9100049

Quality of life in patients on chronic dialysis: self-assessment 3 months after the start of treatment. The Necosad Study Group.

M P Merkus1, K J Jager, F W Dekker, E W Boeschoten, P Stevens, R T Krediet.   

Abstract

The aim of the present multicenter study was to assess quality of life of Dutch dialysis patients 3 months after the start of chronic dialysis treatment. The quality of life was compared with the quality of life of a general population sample, and the impact of demographic, clinical, renal function, and dialysis characteristics on patients' quality of life was studied. New end-stage renal disease (ESRD) patients who were started on chronic hemodialysis or peritoneal dialysis in 13 dialysis centers in The Netherlands were consecutively included. Patients' self-assessment of quality of life was measured by the SF-36, a 36-item Short Form Health Survey Questionnaire encompassing eight dimensions: physical functioning, social functioning, role-functioning physical, role-functioning emotional, mental health, vitality, bodily pain, and general health perceptions. One hundred twenty hemodialysis and 106 peritoneal dialysis patients completed the SF-36. Quality of life of hemodialysis and peritoneal dialysis patients was substantially impaired in comparison to the general population sample, particularly with respect to role-functioning physical and general health perceptions. Mean role-functioning physical and general health perceptions scores of the hemodialysis patients corresponded with the lowest scoring 8% and 12%, respectively, of the reference group. Mean role-functioning physical and general health perceptions scores of the peritoneal dialysis patients corresponded with the lowest scoring 10% and 12%, respectively, of the reference group. Hemodialysis patients showed lower levels of quality of life than peritoneal dialysis patients on physical functioning, role-functioning emotional, mental health, and pain. However, on the multivariate level, we could only demonstrate an impact of dialysis modality on mental health. A higher number of comorbid conditions, a lower hemoglobin level, and a lower residual renal function were independently related to poorer quality of life. The variability of the SF-36 scores explained by selected demographic, clinical, renal function, and dialysis characteristics was highest for physical functioning (29.7%). Explained variability of the other SF-36 dimensions ranged from 6.9% for general health perceptions to 15.4% for vitality. We conclude that quality of life of new ESRD patients is substantially impaired. Comorbid conditions, hemoglobin, and residual renal function could explain poor quality of life only to a limited extent. Further research exploring determinants and indices of quality of life in ESRD patients is warranted. From a clinical perspective, we may conclude that quality of life should be considered in the monitoring of dialysis patients.

Entities:  

Mesh:

Year:  1997        PMID: 9100049     DOI: 10.1016/s0272-6386(97)90342-5

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  71 in total

1.  Assessment of quality of life in a single centre dialysis population using the KDQOL-SF questionnaire.

Authors:  P Carmichael; J Popoola; I John; P E Stevens; A R Carmichael
Journal:  Qual Life Res       Date:  2000-03       Impact factor: 4.147

2.  The SF36 as an outcome measure of services for end stage renal failure.

Authors:  J P Wight; L Edwards; J Brazier; S Walters; J N Payne; C B Brown
Journal:  Qual Health Care       Date:  1998-12

3.  Validation of the KDQOL-SF: a dialysis-targeted health measure.

Authors:  J C Korevaar; M P Merkus; M A M Jansen; F W Dekker; E W Boeschoten; R T Krediet
Journal:  Qual Life Res       Date:  2002-08       Impact factor: 4.147

Review 4.  Opioid and benzodiazepine use in end-stage renal disease: a systematic review.

Authors:  Ahraaz Wyne; Raman Rai; Meaghan Cuerden; William F Clark; Rita S Suri
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-11       Impact factor: 8.237

5.  Risk factors associated with peritoneal dialysis catheter survival: a 9-year single-center study in 315 patients.

Authors:  Namita Singh; Ingemar Davidson; Abu Minhajuddin; Steven Gieser; Michael Nurenberg; Ramesh Saxena
Journal:  J Vasc Access       Date:  2010 Oct-Dec       Impact factor: 2.283

6.  Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients.

Authors:  E Lars Penne; Neelke C van der Weerd; Muriel P C Grooteman; Albert H A Mazairac; Marinus A van den Dorpel; Menso J Nubé; Michiel L Bots; Renée Lévesque; Piet M ter Wee; Peter J Blankestijn
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 8.237

7.  A comparison of SF-36 and SF-12 composite scores and subsequent hospitalization and mortality risks in long-term dialysis patients.

Authors:  Eduardo Lacson; Jianglin Xu; Shu-Fang Lin; Sandie Guerra Dean; J Michael Lazarus; Raymond M Hakim
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-17       Impact factor: 8.237

8.  A comparison of quality of life and travel-related factors between in-center and satellite-based hemodialysis patients.

Authors:  Michael J Diamant; Lori Harwood; Sujana Movva; Barbara Wilson; Larry Stitt; Robert M Lindsay; Louise M Moist
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-17       Impact factor: 8.237

9.  Asymptomatic pulmonary congestion and physical functioning in hemodialysis patients.

Authors:  Giuseppe Enia; Claudia Torino; Vincenzo Panuccio; Rocco Tripepi; Maurizio Postorino; Roberta Aliotta; Marianna Bellantoni; Giovanni Tripepi; Francesca Mallamaci; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-11       Impact factor: 8.237

10.  Depression as a determinant of quality of life in patients with chronic disease: data from Brazil.

Authors:  Luciane Nascimento Cruz; Marcelo Pio de Almeida Fleck; Carisi Anne Polanczyk
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-09-22       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.